RGEN earnings date and last-quarter result: last quarter beat, P/E 153.95. Updated 2026-07-23.
Repligen (RGEN) Research Hub
Repligen (RGEN) trades on NASDAQ, US in the Healthcare (Medical - Instruments & Supplies) sector. As of 2026-10-26, shares last closed at 180.17 USD (+1.83%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 153.95, market cap 7.96B. This hub links to the full technical, earnings and options research available for RGEN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Instruments & Supplies) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 180.17 USD (+1.83%) |
| 52-week range | 125.44 USD – 198.87 USD |
| Trend regime | Range |
| 14-day RSI | 54.9 (Neutral) |
| Trailing P/E | 153.95 |
| Market cap | 7.96B |
| Dividend yield | 0.00% |
Available research for RGEN
Covered Call on RGEN: how it works, illustrative setup around the real 180.17 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RGEN: how it works, illustrative setup around the real 180.17 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RGEN: how it works, illustrative setup around the real 180.17 USD price, max profit/loss, breakeven and when to use it. Educational.
RGEN technical analysis: range, last 180.17 USD, RSI 54.9, 52w range 125.44 USD–198.87 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is RGEN in?
Repligen (RGEN) is classified under Healthcare (Medical - Instruments & Supplies), listed on NASDAQ, US.
Is RGEN in an uptrend or downtrend?
As of 2026-10-26, RGEN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RGEN's trailing P/E ratio?
RGEN's trailing P/E is 153.95, with a market cap of 7.96B. See the earnings research page for full valuation detail.